Lung transplantation: Is it still an experimental procedure?

Current Opinion in Critical Care

Volumn 16, Issue 1, 2010, Pages 53-61

  Boffini, Massimo ^a   Ranieri, Vito M ^a   Rinaldi, Mauro ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Lung transplantation; Marginal donor; Obliterative bronchiolitis; Primary graft dysfunction

Indexed keywords

AZATHIOPRINE; AZITHROMYCIN; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXTRAN DERIVATIVE; LOW POTASSIUM DEXTRAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITRIC OXIDE; RAPAMYCIN; SURFACTANT; TACROLIMUS; UNCLASSIFIED DRUG;

ADD ON THERAPY; ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTIFICIAL VENTILATION; BRONCHIOLITIS OBLITERANS; BRONCHOSCOPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL PROTOCOL; CLINICAL TRIAL; COHORT ANALYSIS; CRITICALLY ILL PATIENT; CRYOPRESERVATION; CYSTIC FIBROSIS; DISEASE COURSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EX VIVO STUDY; EXTRACORPOREAL OXYGENATION; FIBROSING ALVEOLITIS; GRAFT DYSFUNCTION; HUMAN; INCIDENCE; INDUCED HYPOTHERMIA; LIVING DONOR; LUNG GRAFT REJECTION; LUNG LAVAGE; LUNG LOBE; LUNG RESECTION; LUNG TRANSPLANTATION; ORGAN DONOR; OUTCOME ASSESSMENT; PATHOGENESIS; PRIMARY GRAFT DYSFUNCTION; PULMONARY HYPERTENSION; REVIEW; RISK FACTOR; SURGICAL TECHNIQUE;

BRONCHIOLITIS OBLITERANS; HUMANS; LUNG TRANSPLANTATION; PRIMARY GRAFT DYSFUNCTION; SURVIVAL; THERAPIES, INVESTIGATIONAL; TISSUE AND ORGAN PROCUREMENT;

EID: 75149173970     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e32833500a8     Document Type: Review

References (99)

1. Unilateral lung transplantation for pulmonary fibrosis. Toronto Lung Transplant Group. N Engl J Med 1986; 314:1140-1145.
2. Christie JD, Edwards LB, Aurora P, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult lung and heart/ lung transplantation report - 2008. J Heart Lung Transplant 2008; 27:957-969.
3. Chang AC, Orens JB. Are there more lungs available than currently meet the eye? Am J Respir Crit Care Med 2006; 174:624-625.
4. Bhorade SM, Vigneswaran W, McCabe MA, Garrity ER. Liberalization of donor criteria may expand the donor pool without adverse consequence in lung transplantation. J Heart Lung Transplant 2000; 19:1199-1204.
5. Botha P. Extended donor criteria in lung transplantation. Curr Opin Organ Transplant 2009; 14:206-210.
6. Botha P, Fisher AJ, Dark JH. Marginal lung donors: a diminishing margin of safety? Transplantation 2006; 82:1273-1279.
7. Botha P, Rostron AJ, Fisher AJ, Dark JH. Current strategies in donor selection and management. Semin Thorac Cardiovasc Surg 2008; 20:143-151.
8. Christie JD, Kotloff RM, Pochettino A, et al. Clinical risk factors for primary graft failure following lung transplantation. Chest 2003; 124:1232-1241.
9. De Perrot M, Waddell TK, Shargall Y, et al. Impact of donors aged 60 years or more on outcome after lung transplantation: results of an 11-year singlecenter experience. J Thorac Cardiovasc Surg 2007; 133:525-531.
10. Fischer S, Gohrbandt B, Struckmeier P, et al. Lung transplantation with lungs from donors fifty years of age and older. J Thorac Cardiovasc Surg 2005; 129:919-925.
11. Novick RJ, Bennett LE, Meyer DM, Hosenpud JD. Influence of graft ischemic time and donor age on survival after lung transplantation. J Heart Lung Transplant 1999; 18:425-431.
12. Novitzky D, Wicomb WN, Rose AG, et al. Pathophysiology of pulmonary edema following experimental brain death in the chacma baboon. Ann Thorac Surg 1987; 43:288-294.
13. Fisher AJ, Donnelly SC, Hirani N, et al. Enhanced pulmonary inflammation in organ donors following fatal nontraumatic brain injury. Lancet 1999; 353:1412-1413.
14. Gabbay E, Williams TJ, Griffiths AP, et al. Maximizing the utilization of donor organs offered for lung transplantation. Am J Respir Crit Care Med 1999; 160:265-271.
15. Fiser SM, Kron IL, Long SM, et al. Donor lung salvage after neurogenic pulmonary edema with the use of posttransplant extracorporeal membrane oxygenation. J Thorac Cardiovasc Surg 2001; 122:1257-1258.
16. McGiffin DC, Zorn GL Jr, Young KR Jr, et al. The intensive care unit oxygen challenge should not be used for donor lung function decision-making. J Heart Lung Transplant 2005; 24:1902-1905.
17. Aziz TM, El-Gamel A, Saad RA, et al. Pulmonary vein gas analysis for assessing donor lung function. Ann Thorac Surg 2002; 73:1599-1604; discussion 1604-11595
18. Botha P, Trivedi D, Searl CP, et al. Differential pulmonary vein gases predict primary graft dysfunction. Ann Thorac Surg 2006; 82:1998-2002.
19. Oto T, Griffiths AP, Levvey B, et al. A donor history of smoking affects early but not late outcome in lung transplantation. Transplantation 2004; 78:599-606.
20. Weill D, Dey GC, Hicks RA, et al. A positive donor gram stain does not predict outcome following lung transplantation. J Heart Lung Transplant 2002; 21:555-558.
21. Love RB, Stringham J, Chomiak PN, et al. First successful lung transplantation using a nonheart beating donor [abstract]. J Heart Lung Transplant 1995; 14 (Suppl):S88.
22. Alessandrini F, D'Armini AM, Roberts CS, et al. When does the lung die? II. Ultrastructural evidence of pulmonary viability after 'death'. J Heart Lung Transplant 1994; 13:748-757.
23. D'Armini AM, Roberts CS, Griffith PK, et al. When does the lung die? I. Histochemical evidence of pulmonary viability after 'death'. J Heart Lung Transplant 1994; 13:741-747.
24. Egan TM, Lambert CJ Jr, Reddick R, et al. A strategy to increase the donor pool: use of cadaver lungs for transplantation. Ann Thorac Surg 1991; 52:1113-1120; discussion 1120-11111
25. Kootstra G, Daemen JH, Oomen AP. Categories of nonheart-beating donors. Transplant Proc 1995; 27:2893-2894.
26. Egan TM. Nonheart-beating donors in thoracic transplantation. J Heart Lung Transplant 2004; 23:3-10.
27. Gamez P, Cordoba M, Ussetti P, et al. Lung transplantation from out-ofhospital nonheart-beating lung donors. One-year experience and results. J Heart Lung Transplant 2005; 24:1098-1102.
28. Loehe F, Mueller C, Annecke T, et al. Pulmonary graft function after long-term preservation of nonheart-beating donor lungs. Ann Thorac Surg 2000; 69:1556-1562.
29. Mason DP, Murthy SC, Gonzalez-Stawinski GV, et al. Early experience with lung transplantation using donors after cardiac death. J Heart Lung Transplant 2008; 27:561-563.
30. Oto T, Levvey B, McEgan R, et al. A practical approach to clinical lung transplantation from a Maastricht category III donor with cardiac death. J Heart Lung Transplant 2007; 26:196-199.
31. Steen S, Ingemansson R, Budrikis A, et al. Successful transplantation of lungs topically cooled in the nonheart-beating donor for 6 h. Ann Thorac Surg 1997; 63:345-351.
32. Steen S, Liao Q, Wierup PN, et al. Transplantation of lungs from nonheartbeating donors after functional assessment ex vivo. Ann Thorac Surg 2003; 76:244-252; discussion 252.
33. Mason DP, Thuita L, Alster JM, et al. Should lung transplantation be performed using donation after cardiac death? The United States experience. J Thorac Cardiovasc Surg 2008; 136:1061-1066.
34. De Vleeschauwer S, Van Raemdonck D, Vanaudenaerde B. Early outcome after lung transplantation from nonheart-beating donors is comparable to heart-beating donors. J Heart Lung Transplant 2009; 28:380-387.
35. Avlonitis VS, Fisher AJ, Kirby JA, Dark JH. Pulmonary transplantation: the role of brain death in donor lung injury. Transplantation 2003; 75:1928-1933.
36. Nijkamp DM, van der Bij W, Verschuuren EA, et al. Nonheart-beating lung donation: how big is the pool? J Heart Lung Transplant 2008; 27:1040-1042.
37. Angel LF, Levine DJ, Restrepo MI, et al. Impact of a lung transplantation donormanagement protocol on lung donation and recipient outcomes. Am J Respir Crit Care Med 2006; 174:710-716.
38. Puri V, Patterson GA. Adult lung transplantation: technical considerations. Semin Thorac Cardiovasc Surg 2008; 20:152-164.
39. Barr ML, Schenkel FA, Bowdish ME, Starnes VA. Living donor lobar lung transplantation: current status and future directions. Transplant Proc 2005; 37:3983-3986.
40. Yamane M, Date H, Okazaki M, et al. Long-term improvement in pulmonary function after living donor lobar lung transplantation. J Heart Lung Transplant 2007; 26:687-692.
41. Couetil JP, Tolan MJ, Loulmet DF, et al. Pulmonary bipartitioning and lobar transplantation: a new approach to donor organ shortage. J Thorac Cardiovasc Surg 1997; 113:529-537.
42. Steen S, Sjoberg T, Pierre L, et al. Transplantation of lungs from a nonheartbeating donor. Lancet 2001; 357:825-829.
43. Wierup P, Haraldsson A, Nilsson F, et al. Ex vivo evaluation of nonacceptable donor lungs. Ann Thorac Surg 2006; 81:460-466.
44. Ingemansson R, Eyjolfsson A, Mared L, et al. Clinical transplantation of initially rejected donor lungs after reconditioning ex vivo. Ann Thorac Surg 2009; 87:255-260.
45. Christie JD, Carby M, Bag R, et al. Report of the ISHLT working group on primary lung graft dysfunction part II: definition. A consensus statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2005; 24:1454-1459.
46. Lee JC, Christie JD. Primary graft dysfunction. Proc Am Thorac Soc 2009; 6:39-46.
47. Carter YM, Gelman AE, Kreisel D. Pathogenesis, management, and consequences of primary graft dysfunction. Semin Thorac Cardiovasc Surg 2008; 20:165-172.
48. Oto T, Levvey BJ, Snell GI. Potential refinements of the International Society for Heart and Lung Transplantation primary graft dysfunction grading system. J Heart Lung Transplant 2007; 26:431-436.
49. Whitson BA, Nath DS, Johnson AC, et al. Risk factors for primary graft dysfunction after lung transplantation. J Thorac Cardiovasc Surg 2006; 131:73-80.
50. Kuntz CL, Hadjiliadis D, Ahya VN, et al. Risk factors for early primary graft dysfunction after lung transplantation: a registry study. Clin Transplant 2009 [Epub ahead of print].
51. Suzuki S, Inoue K, Sugita M, et al. Effects of EP4 solution and LPD solution vs Euro-Collins solution on Na(+)/K(+)-ATPase activity in rat alveolar type II cells and human alveolar epithelial cell line A549 cells. J Heart Lung Transplant 2000; 19:887-893.
52. Fischer S, Matte-Martyn A, De Perrot M, et al. Low-potassium dextran preservation solution improves lung function after human lung transplantation. J Thorac Cardiovasc Surg 2001; 121:594-596.
53. Muller C, Furst H, Reichenspurner H, et al. Lung procurement by lowpotassium dextran and the effect on preservation injury. Munich Lung Transplant Group. Transplantation 1999; 68:1139-1143.
54. Struber M, Hohlfeld JM, Fraund S, et al. Low-potassium dextran solution ameliorates reperfusion injury of the lung and protects surfactant function. J Thorac Cardiovasc Surg 2000; 120:566-572.
55. Struber M, Wilhelmi M, Harringer W, et al. Flush perfusion with low potassium dextran solution improves early graft function in clinical lung transplantation. Eur J Cardiothorac Surg 2001; 19:190-194.
56. Aziz TM, Pillay TM, Corris PA, et al. Perfadex for clinical lung procurement: is it an advance? Ann Thorac Surg 2003; 75:990-995.
57. Nath DS, Walter AR, Johnson AC, et al. Does Perfadex affect outcomes in clinical lung transplantation? J Heart Lung Transplant 2005; 24:2243-2248.
58. Thabut G, Mal H, Cerrina J, et al. Graft ischemic time and outcome of lung transplantation: a multicenter analysis. Am J Respir Crit Care Med 2005; 171:786-791. (Pubitemid 40471151)
59. Oto T, Griffiths AP, Rosenfeldt F, et al. Early outcomes comparing Perfadex, Euro-Collins, and Papworth solutions in lung transplantation. Ann Thorac Surg 2006; 82:1842-1848.
60. Ferraro P, Martin J, Dery J, et al. Late retrograde perfusion of donor lungs does not decrease the severity of primary graft dysfunction. Ann Thorac Surg 2008; 86:1123-1129.
61. Sarsam MA, Yonan NA, Deiraniya AK, Rahman AN. Retrograde pulmonaryplegia for lung preservation in clinical transplantation: a new technique. J Heart Lung Transplant 1993; 12:494-498.
62. Baretti R, Bitu-Moreno J, Beyersdorf F, et al. Distribution of lung preservation solutions in parenchyma and airways: influence of atelectasis and route of delivery. J Heart Lung Transplant 1995; 14:80-91.
63. DeCampos KN, Keshavjee S, Liu M, Slutsky AS. Prevention of rapid reperfusion- induced lung injury with prostaglandin E1 during the initial period of reperfusion. J Heart Lung Transplant 1998; 17:1121-1128.
64. Schnickel GT, Ross DJ, Beygui R, et al. Modified reperfusion in clinical lung transplantation: the results of 100 consecutive cases. J Thorac Cardiovasc Surg 2006; 131:218-223.
65. Adatia I, Lillehei C, Arnold JH, et al. Inhaled nitric oxide in the treatment of postoperative graft dysfunction after lung transplantation. Ann Thorac Surg 1994; 57:1311-1318.
66. Date H, Triantafillou AN, Trulock EP, et al. Inhaled nitric oxide reduces human lung allograft dysfunction. J Thorac Cardiovasc Surg 1996; 111:913-919.
67. Macdonald P, Mundy J, Rogers P, et al. Successful treatment of life-threatening acute reperfusion injury after lung transplantation with inhaled nitric oxide. J Thorac Cardiovasc Surg 1995; 110:861-863.
68. Garat C, Jayr C, Eddahibi S, et al. Effects of inhaled nitric oxide or inhibition of endogenous nitric oxide formation on hyperoxic lung injury. Am J Respir Crit Care Med 1997; 155:1957-1964.
69. Amital A, Shitrit D, Raviv Y, et al. Surfactant as salvage therapy in life threatening primary graft dysfunction in lung transplantation. Eur J Cardiothorac Surg 2009; 35:299-303.
70. Amital A, Shitrit D, Raviv Y, et al. The use of surfactant in lung transplantation. Transplantation 2008; 86:1554-1559.
71. Bermudez CA, Adusumilli PS, McCurry KR, et al. Extracorporeal membrane oxygenation for primary graft dysfunction after lung transplantation: long-term survival. Ann Thorac Surg 2009; 87:854-860.
72. Fiser SM, Kron IL, McLendon Long S, et al. Early intervention after severe oxygenation index elevation improves survival following lung transplantation. J Heart Lung Transplant 2001; 20:631-636.
73. Meyers BF, Sundt TM 3rd, Henry S, et al. Selective use of extracorporeal membrane oxygenation is warranted after lung transplantation. J Thorac Cardiovasc Surg 2000; 120:20-26.
74. Shargall Y, Guenther G, Ahya VN, et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part VI: treatment. J Heart Lung Transplant 2005; 24:1489-1500.
75. Belperio JA, Weigt SS, Fishbein MC, Lynch JP 3rd. Chronic lung allograft rejection: mechanisms and therapy. Proc Am Thorac Soc 2009; 6:108-121.
76. Grossman EJ, Shilling RA. Bronchiolitis obliterans in lung transplantation: the good, the bad, and the future. Transl Res 2009; 153:153-165.
77. Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002; 21:297-310.
78. Estenne M, Van Muylem A, Knoop C, Antoine M. Detection of obliterative bronchiolitis after lung transplantation by indexes of ventilation distribution. Am J Respir Crit Care Med 2000; 162:1047-1051.
79. Stewart S, Fishbein MC, Snell GI, et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant 2007; 26:1229-1242. (Pubitemid 350256994)
80. Saggar R, Ross DJ, Saggar R, et al. Pulmonary hypertension associated with lung transplantation obliterative bronchiolitis and vascular remodeling of the allograft. Am J Transplant 2008; 8:1921-1930.
81. Belperio JA, Lake K, Tazelaar H, et al. Bronchiolitis obliterans syndrome complicating lung or heart-lung transplantation. Semin Respir Crit Care Med 2003; 24:499-530.
82. Knoop C, Estenne M. Acute and chronic rejection after lung transplantation. Semin Respir Crit Care Med 2006; 27:521-533.
83. Daud SA, Yusen RD, Meyers BF, et al. Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2007; 175:507-513.
84. Glanville AR, Gencay M, Tamm M, et al. Chlamydia pneumoniae infection after lung transplantation. J Heart Lung Transplant 2005; 24:131-136.
85. Mikols CL, Yan L, Norris JY, et al. IL-12 p80 is an innate epithelial cell effector that mediates chronic allograft dysfunction. Am J Respir Crit Care Med 2006; 174:461-470.
86. Rizzo M, Alevy YG, Sundaresan S, et al. Increased expression of HDJ-2 (heat shock protein 40) and heat shock protein 70 in biopsy specimens of transplanted human lungs. J Heart Lung Transplant 1998; 17:241-249.
87. Bando K, Paradis IL, Similo S, et al. Obliterative bronchiolitis after lung and heart-lung transplantation. An analysis of risk factors and management. J Thorac Cardiovasc Surg 1995; 110:4-13; discussion 13-14.
88. Heng D, Sharples LD, McNeil K, et al. Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors. J Heart Lung Transplant 1998; 17:1255-1263.
89. Husain AN, Siddiqui MT, Holmes EW, et al. Analysis of risk factors for the development of bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 1999; 159:829-833.
90. Scott AI, Sharples LD, Stewart S. Bronchiolitis obliterans syndrome: risk factors and therapeutic strategies. Drugs 2005; 65:761-771.
91. Verleden GM, Dupont LJ, Van Raemdonck DE. Is it bronchiolitis obliterans syndrome or is it chronic rejection: a reappraisal? Eur Respir J 2005; 25:221-224.
92. Glanville AR, Aboyoun CL, Havryk A, et al. Severity of lymphocytic bronchiolitis predicts long-term outcome after lung transplantation. Am J Respir Crit Care Med 2008; 177:1033-1040.
93. Palmer SM, Davis RD, Hadjiliadis D, et al. Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome. Transplantation 2002; 74:799-804.
94. Jackson CH, Sharples LD, McNeil K, et al. Acute and chronic onset of bronchiolitis obliterans syndrome (BOS): are they different entities? J Heart Lung Transplant 2002; 21:658-666.
95. Lama VN, Murray S, Lonigro RJ, et al. Course of FEV(1) after onset of bronchiolitis obliterans syndrome in lung transplant recipients. Am J Respir Crit Care Med 2007; 175:1192-1198.
96. Vermeulen KM, Groen H, van der Bij W, et al. The effect of bronchiolitis obliterans syndrome on health related quality of life. Clin Transplant 2004; 18:377-383.
97. Aigner C, Jaksch P, Taghavi S, et al. Pulmonary retransplantation: is it worth the effort? A long-term analysis of 46 cases. J Heart Lung Transplant 2008; 27:60-65.
98. Kawut SM, Lederer DJ, Keshavjee S, et al. Outcomes after lung retransplantation in the modern era. Am J Respir Crit Care Med 2008; 177:114-120.
99. Estenne M, Hertz MI. Bronchiolitis obliterans after human lung transplantation. Am J Respir Crit Care Med 2002; 166:440-444.